Abstract
A Fullerene based system is modified in order to increase its solubility and enhance its ability to carry a protein-like structure. The modified structure, which is proposed to act as HIV-1 protease inhibitor, is [C60–C2H4N–(2,4- XCOCH2OH)C6H4], where the X atom is either O, S or Se. The geometry optimization, vibrational spectra and thermodynamics were performed using semiempirical quantum mechanical PM3 method in order to study the proposed compounds. Furthermore, the quantitative structure activity relationship (QSAR) properties of the compounds are calculated at the same level of theory. Results indicate a possible use of the investigated structures as HIV-1 protease inhibitors. The compounds containing oxygen is more stable as compared to the other two compounds.
Keywords: Fulleropyrrolidine, HIV-1 Protease, Hydroxymethylcarbonyl group (HMC), Molecular modeling, QSAR, hydrophilic, chalcogen atoms, polarizability, hydroxyl groups, agrochemicals, mono-functionalization, ring-junction
Mini-Reviews in Medicinal Chemistry
Title:Fullerene Derivative as Anti-HIV Protease Inhibitor: Molecular Modeling and QSAR Approaches
Volume: 12 Issue: 6
Author(s): M. Ibrahim, N. A. Saleh, W. M. Elshemey and A. A. Elsayed
Affiliation:
Keywords: Fulleropyrrolidine, HIV-1 Protease, Hydroxymethylcarbonyl group (HMC), Molecular modeling, QSAR, hydrophilic, chalcogen atoms, polarizability, hydroxyl groups, agrochemicals, mono-functionalization, ring-junction
Abstract: A Fullerene based system is modified in order to increase its solubility and enhance its ability to carry a protein-like structure. The modified structure, which is proposed to act as HIV-1 protease inhibitor, is [C60–C2H4N–(2,4- XCOCH2OH)C6H4], where the X atom is either O, S or Se. The geometry optimization, vibrational spectra and thermodynamics were performed using semiempirical quantum mechanical PM3 method in order to study the proposed compounds. Furthermore, the quantitative structure activity relationship (QSAR) properties of the compounds are calculated at the same level of theory. Results indicate a possible use of the investigated structures as HIV-1 protease inhibitors. The compounds containing oxygen is more stable as compared to the other two compounds.
Export Options
About this article
Cite this article as:
Ibrahim M., A. Saleh N., M. Elshemey W. and A. Elsayed A., Fullerene Derivative as Anti-HIV Protease Inhibitor: Molecular Modeling and QSAR Approaches, Mini-Reviews in Medicinal Chemistry 2012; 12 (6) . https://dx.doi.org/10.2174/138955712800493762
DOI https://dx.doi.org/10.2174/138955712800493762 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sevoflurane in Intraoperative and Postoperative Cardiac Surgery Patients. Our Experience in Intensive Care Unit with Sevoflurane Sedation
Current Pharmaceutical Design Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Synthetic and Natural Products as Iron Chelators
Current Topics in Medicinal Chemistry Genetics and Gene Therapy of Anderson-Fabry Disease
Current Gene Therapy Novel Therapies for Asthma - Advances and Problems
Current Pharmaceutical Design A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Neuroprotection and Behavior Regulation by Adrenomedullin and PAMP as Shown by Conditional Knockout Models
Current Hypertension Reviews Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy
Current Drug Metabolism Neuronal Regulation of Aortic Valve Cusps
Current Vascular Pharmacology Staged Starnes Operation Preserving Patent Ductus Arteriosus for Neonates with Ebsteins Anomaly and Pulmonary Atresia
Current Cardiology Reviews DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Neuroendocrine Tumors of the Lung: Hystological Classification, Diagnosis, Traditional and New Therapeutic Approaches
Current Medicinal Chemistry Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?
Anti-Cancer Agents in Medicinal Chemistry